Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.

Neubert NJ, Schmittnaegel M, Bordry N, Nassiri S, Wald N, Martignier C, Tillé L, Homicsko K, Damsky W, Maby-El Hajjami H, Klaman I, Danenberg E, Ioannidou K, Kandalaft L, Coukos G, Hoves S, Ries CH, Fuertes Marraco SA, Foukas PG, De Palma M, Speiser DE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaan3311. doi: 10.1126/scitranslmed.aan3311.

PMID:
29643229
2.

Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.

Cardoso E, Mercier T, Wagner AD, Homicsko K, Michielin O, Ellefsen-Lavoie K, Cagnon L, Diezi M, Buclin T, Widmer N, Csajka C, Decosterd L.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Apr 15;1083:124-136. doi: 10.1016/j.jchromb.2018.02.008. Epub 2018 Feb 8.

PMID:
29544202
3.

Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma".

Voruz S, Martins F, Cairoli A, Naveiras O, Homicsko K, Missiaglia E, de Leval L, Bisig B, Michielin O, Blum S.

Haematologica. 2018 Mar;103(3):e130. doi: 10.3324/haematol.2017.186932. No abstract available.

4.

Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.

Viala M, Vinches M, Alexandre M, Mollevi C, Durigova A, Hayaoui N, Homicsko K, Cuenant A, Gongora C, Gianni L, Tosi D.

Br J Cancer. 2018 Mar 6;118(5):679-697. doi: 10.1038/bjc.2017.473. Epub 2018 Feb 13.

PMID:
29438365
5.

Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.

Voruz S, Cairoli A, Naveiras O, de Leval L, Missiaglia E, Homicsko K, Michielin O, Blum S.

Haematologica. 2018 Jan;103(1):e39-e41. doi: 10.3324/haematol.2017.179150. Epub 2017 Nov 2. No abstract available.

6.

Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma.

Fankhauser M, Broggi MAS, Potin L, Bordry N, Jeanbart L, Lund AW, Da Costa E, Hauert S, Rincon-Restrepo M, Tremblay C, Cabello E, Homicsko K, Michielin O, Hanahan D, Speiser DE, Swartz MA.

Sci Transl Med. 2017 Sep 13;9(407). pii: eaal4712. doi: 10.1126/scitranslmed.aal4712.

PMID:
28904226
7.

Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors.

Stathis A, Hess D, von Moos R, Homicsko K, Griguolo G, Joerger M, Mark M, Ackermann CJ, Allegrini S, Catapano CV, Xyrafas A, Enoiu M, Berardi S, Gargiulo P, Sessa C; Swiss Group for Clinical Cancer Research (SAKK).

Invest New Drugs. 2017 Dec;35(6):766-772. doi: 10.1007/s10637-017-0454-z. Epub 2017 Mar 20.

PMID:
28317088
8.

Combine and Conquer: Double CTLA-4 and PD-1 Blockade Combined with Whole Tumor Antigen Vaccine Cooperate to Eradicate Tumors.

Homicsko K, Duraiswamy J, Doucey MA, Coukos G.

Cancer Res. 2016 Dec 1;76(23):6765-6767. No abstract available.

9.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y.

ESMO Open. 2016 Sep 29;1(5):e000097. eCollection 2016. Review.

10.

Compact solid-state CMOS single-photon detector array for in vivo NIR fluorescence lifetime oncology measurements.

Homulle HA, Powolny F, Stegehuis PL, Dijkstra J, Li DU, Homicsko K, Rimoldi D, Muehlethaler K, Prior JO, Sinisi R, Dubikovskaya E, Charbon E, Bruschini C.

Biomed Opt Express. 2016 Apr 11;7(5):1797-814. doi: 10.1364/BOE.7.001797. eCollection 2016 May 1.

11.

Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).

Wick W, Gorlia T, Bady P, Platten M, van den Bent MJ, Taphoorn MJ, Steuve J, Brandes AA, Hamou MF, Wick A, Kosch M, Weller M, Stupp R, Roth P, Golfinopoulos V, Frenel JS, Campone M, Ricard D, Marosi C, Villa S, Weyerbrock A, Hopkins K, Homicsko K, Lhermitte B, Pesce G, Hegi ME.

Clin Cancer Res. 2016 Oct 1;22(19):4797-4806. Epub 2016 May 3.

12.

Targeting Programmed Cell Death 1 in Ovarian Cancer.

Homicsko K, Coukos G.

J Clin Oncol. 2015 Dec 1;33(34):3987-9. doi: 10.1200/JCO.2015.63.7785. Epub 2015 Oct 26. No abstract available.

PMID:
26503205
13.

The consensus molecular subtypes of colorectal cancer.

Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S.

Nat Med. 2015 Nov;21(11):1350-6. doi: 10.1038/nm.3967. Epub 2015 Oct 12.

14.

[New melanoma immunotherapies: mechanisms of action, efficiency and management of toxicities].

Moura B, Homicsko K, Berthod G, Cerottini JP, Guggisberg D, Gaide O, Maillard MH, Michielin O.

Rev Med Suisse. 2015 May 20;11(475):1108, 1110-4. Review. French.

PMID:
26152085
15.

Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies.

Tosi D, Laghzali Y, Vinches M, Alexandre M, Homicsko K, Fasolo A, Del Conte G, Durigova A, Hayaoui N, Gourgou S, Gianni L, Mollevi C.

J Clin Oncol. 2015 Jul 1;33(19):2158-65. doi: 10.1200/JCO.2014.58.1082. Epub 2015 May 26. Review.

PMID:
26014300
16.

MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.

Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W; DIRECTOR Study Group.

Clin Cancer Res. 2015 May 1;21(9):2057-64. doi: 10.1158/1078-0432.CCR-14-2737. Epub 2015 Feb 5.

17.

Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.

Peters S, Bouchaab H, Zimmerman S, Bucher M, Gaide O, Letovanec I, Homicsko K, Michielin O.

Melanoma Res. 2014 Oct;24(5):496-500. doi: 10.1097/CMR.0000000000000055.

PMID:
25185693
18.

Standards of care and novel approaches in the management of glioblastoma multiforme.

Hottinger AF, Stupp R, Homicsko K.

Chin J Cancer. 2014 Jan;33(1):32-9. doi: 10.5732/cjc.013.10207. Review.

19.

A colorectal cancer classification system that associates cellular phenotype and responses to therapy.

Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M, Lhermitte B, Olshen AB, Wiedenmann B, Cantley LC, Gray JW, Hanahan D.

Nat Med. 2013 May;19(5):619-25. doi: 10.1038/nm.3175. Epub 2013 Apr 14.

20.

PET Imaging in Glioma: The Neuro-Oncologist's Expectations.

Hottinger AF, Levivier M, Negretti L, Homicsko K, Stupp R.

PET Clin. 2013 Apr;8(2):117-28. doi: 10.1016/j.cpet.2012.09.006. Epub 2012 Nov 28.

PMID:
27157943
21.

Decision making and management of gliomas: practical considerations.

Hottinger AF, Homicsko K, Negretti L, Lhermitte B, Stupp R.

Ann Oncol. 2012 Sep;23 Suppl 10:x33-40.

PMID:
22987986
22.

[Melanoma: a new therapeutic era].

Berthod G, Homicsko K, Bouchaab H, Matter M, Cerottini JP, Guggisberg D, Speiser D, Leyvraz S, Michielin O.

Rev Med Suisse. 2011 May 25;7(296):1126-30. Review. French.

PMID:
21721201
23.

Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers.

Homicsko K, Berthold DR.

Anticancer Drugs. 2011 Jan;22 Suppl 1:S4-8. doi: 10.1097/01.cad.0000390766.47540.07. Review.

PMID:
21173604
24.

Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus.

Bazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R, Iggo R, Homicsko K, Fisher KD, Halldén G, Mautner V, Shen Y, Seymour LW.

Hum Gene Ther. 2008 Sep;19(9):873-86. doi: 10.1089/hum.2008.047.

PMID:
18710328
25.
26.

RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer.

Homicsko K, Lukashev A, Iggo RD.

Cancer Res. 2005 Aug 1;65(15):6882-90.

27.

Binding site of salsolinol: its properties in different regions of the brain and the pituitary gland of the rat.

Homicskó KG, Kertész I, Radnai B, Tóth BE, Tóth G, Fülöp F, Fekete MI, Nagy GM.

Neurochem Int. 2003 Jan;42(1):19-26.

PMID:
12441164
28.

Physiological role of salsolinol: its hypophysiotrophic function in the regulation of pituitary prolactin secretion.

Tóth BE, Bodnár I, Homicskó KG, Fülöp F, Fekete MI, Nagy GM.

Neurotoxicol Teratol. 2002 Sep-Oct;24(5):655-66. Review.

PMID:
12200196
29.

Salsolinol is a putative endogenous neuro-intermediate lobe prolactin-releasing factor.

Tóth BE, Homicskó K, Radnai B, Maruyama W, DeMaria JE, Vecsernyés M, Fekete MI, Fülöp F, Naoi M, Freeman ME, Nagy GM.

J Neuroendocrinol. 2001 Dec;13(12):1042-50.

PMID:
11722700

Supplemental Content

Loading ...
Support Center